Dabaghian Mehran, Latify Ali Mohammad, Tebianian Majid, Nili Hassan, Ranjbar Ali Reza Tevangar, Mirjalili Ali, Mohammadi Mashallah, Banihashemi Reza, Ebrahimi Seyyed Mahmoud
Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, PO Box 14155-3651, Tehran, Iran; Department of Pathobiology, University of Tehran, Faculty of Veterinary Medicine, PO Box 14155-6453, Tehran, Iran.
Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, PO Box 14155-3651, Tehran, Iran.
Vet Microbiol. 2014 Nov 7;174(1-2):116-26. doi: 10.1016/j.vetmic.2014.09.009. Epub 2014 Sep 23.
As cellular immunity is essential for virus clearance, it is commonly accepted that no adequate cellular immunity is achieved by all available inactivated HA-based influenza vaccines. Thus, an improved influenza vaccine to induce both humoral and cell-mediated immune responses is urgently required to control LPAI H9N2 outbreaks in poultry farms. M2e-based vaccines have been suggested and developed as a new generation of universal vaccine candidate against influenza A infection. Our previous study have shown that a prime-boost administration of recombinant 4×M2e.HSP70c (r4M2e/H70c) fusion protein compared to conventional HA-based influenza vaccines provided full protection against lethal dose of influenza A viruses in mice. In the present study, the immunogenicity and protective efficacy of (r4M2e/H70c) was examined in chickens. The data reported herein show that protection against H9N2 viral challenge was significantly increased in chickens by injection of r4M2e/H70c compared with injection of conventional HA-based influenza vaccine adjuvanted with MF59 or recombinant 4×M2e (r4M2e) without HSP70c. Oropharyngeal and cloacal shedding of the virus was detected in all of the r4M2e/H70c vaccinated birds at 2 days after challenge, but the titer was low and decreased rapidly to reach undetectable levels at 7 days after challenge. Moreover, comparison of protective efficacy against LPAI H9N2 in birds intramuscularly immunized with r4M2e/H70c likely represented the ability of the M2e-based vaccine in providing cross-protection against heterosubtypic H9N2 challenge and also allowed the host immune system to induce HA-homosubtype neutralizing antibody against H9N2 challenge. This protective immunity might be attributed to enhanced cell-mediated immunity, which is interpreted as increased lymphocytes proliferation, increased levels of Th1-type (IFN-γ) and Th2-type (IL-4) cytokines production and increased CD4(+) to CD8(+) ratios, resulting from the injection of four tandem repeats of the ectodomain of the conserved influenza matrix protein M2 (4×M2e) genetically fused to C-terminus of Mycobacterium tuberculosis HSP70 (mHSP70c).
由于细胞免疫对于病毒清除至关重要,人们普遍认为现有的所有基于血凝素(HA)的灭活流感疫苗都无法产生足够的细胞免疫。因此,迫切需要一种能诱导体液免疫和细胞介导免疫反应的改良型流感疫苗,以控制家禽养殖场低致病性禽流感(LPAI)H9N2疫情的爆发。基于M2e的疫苗已被提出并开发为新一代抗甲型流感感染的通用疫苗候选物。我们之前的研究表明,与传统的基于HA的流感疫苗相比,重组4×M2e.HSP70c(r4M2e/H70c)融合蛋白的初免-加强免疫方案能为小鼠提供针对致死剂量甲型流感病毒的完全保护。在本研究中,检测了(r4M2e/H70c)在鸡体内的免疫原性和保护效果。本文报道的数据表明,与注射用MF59佐剂的传统基于HA的流感疫苗或不含HSP70c的重组4×M2e(r4M2e)相比,注射r4M2e/H70c可显著提高鸡对H9N2病毒攻击的抵抗力。在攻毒后2天,在所有接种r4M2e/H70c的鸡中均检测到口咽和泄殖腔病毒 shedding,但滴度较低,并在攻毒后7天迅速下降至检测不到的水平。此外,对用r4M2e/H70c进行肌肉免疫的鸡针对LPAI H9N2的保护效果进行比较,可能代表了基于M2e的疫苗提供针对异型H9N2攻击的交叉保护的能力,也使宿主免疫系统能够诱导针对H9N2攻击的HA同型中和抗体。这种保护性免疫可能归因于细胞介导免疫的增强,这表现为淋巴细胞增殖增加、Th1型(IFN-γ)和Th2型(IL-4)细胞因子产生水平增加以及CD4(+)与CD8(+)比值增加,这是由于将保守的流感基质蛋白M2(4×M2e)的胞外域的四个串联重复序列与结核分枝杆菌HSP70(mHSP70c)的C末端基因融合注射所致。